ERBB2 and breast cancer: A phase I study in Japanese patients showed that taselisib was well tolerated at 6 mg daily in patients with advanced solid tumor, and 4 mg daily in combination with fulvestrant in patients with HR-positive, HER2-negative advanced/recurrent breast cancer [149].